Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 0.43 |
| ▸ | CPT2 | P23786 | 1/20 | 0.36 |
| ▸ | CPT1A | P50416 | 1/20 | 0.36 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ATF4 | P18848 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6362596 | 0.88 | F10 (0.43) | F10CPT2CPT1ACPT1BEPHX2 | |
| SCHEMBL14817815 | 0.85 | F10 (0.46) | F10EPHX2SMN1; SMN2L3MBTL1MCHR1 | |
| SCHEMBL4265640 | 0.83 | F10 (0.47) | F10EPHX2SMN1; SMN2L3MBTL1USP30 | |
| SCHEMBL4265643 | 0.83 | F10 (0.47) | F10EPHX2SMN1; SMN2L3MBTL1USP30 | |
| SCHEMBL2944327 | 0.82 | F10 (0.61) | F10 | |
| SCHEMBL2935606 | 0.82 | F10 (0.61) | F10 | |
| SCHEMBL6361887 | 0.78 | F10 (0.39) | F10EPHX2SMN1; SMN2L3MBTL1USP30 | |
| SCHEMBL6362439 | 0.77 | EPHX2 (0.40) | F10EPHX2SMN1; SMN2L3MBTL1ATF4 | |
| SCHEMBL1253959 | 0.77 | F10 (0.73) | F10 | |
| SCHEMBL1253957 | 0.77 | F10 (0.73) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | F10 196/4885CPT2 2184/4885CPT1A 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.